FDA - Notice of Intent to Sole Source -Biosimilar Education for Patients and Healthcare Providers: Medscape and WebMD
ID: FDA-SoleSource-126418Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFFOOD AND DRUG ADMINISTRATIONRockville, MD, 20841, US

NAICS

Professional and Management Development Training (611430)

Original Source

https://sam.gov/opp/16d926e6962e4efabfd99fb56245f653/view
Timeline
    Description

    The Food and Drug Administration (FDA) intends to make a sole source award to WebMD Health Corp. for the development and provision of "Biosimilar Education for Patients and Healthcare Providers." This initiative aims to create accredited continuing education content for healthcare providers, including doctors, pharmacists, and nurses, focusing on biosimilars and interchangeable products, covering their development, regulatory review, clinical outcomes, and practical applications. The educational effort is crucial for enhancing clinical competency among providers, thereby increasing their confidence in prescribing and using biosimilars, as well as educating patients. Interested parties can contact Sheila Brown at sheila.brown1@fda.hhs.gov or Ian Weiss at ian.weiss@fda.hhs.gov for further information.

    Point(s) of Contact
    Sheila Brown
    sheila.brown1@fda.hhs.gov
    Ian Weiss
    ian.weiss@fda.hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    MentorcliQ, brand name or equal.
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking small businesses capable of providing Commercial Off-the-Shelf software licenses for MentorcliQ or equivalent solutions through a Request for Information (RFI). The FDA aims to enhance its mentoring program by acquiring a SaaS cloud-based platform that is interoperable with Google Cloud, supports single sign-on, accommodates up to 19,000 users, and complies with Section 508 accessibility standards. This RFI is intended for information and market research purposes only and does not constitute a solicitation or contract award; responses must be submitted by January 20, 2025, to Min Jie Zeng at minjie.zeng@fda.hhs.gov and Lilibeth Deato at Lilibeth.Deato@fda.hhs.gov.
    Access to Outpatient Longitudinal Drug Utilization Data
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide access to outpatient longitudinal drug utilization data through a Sources Sought notice. The primary objective is to acquire existing, HIPAA-compliant data resources that will enhance drug safety evaluations, support post-market surveillance, and inform regulatory decisions, rather than developing new databases. This initiative is crucial for monitoring medication utilization trends, particularly in areas such as opioid surveillance, and aims to improve public health outcomes through rigorous analyses of drug safety data. Interested firms must submit their responses by January 23, 2025, including their business size status and DUNS number, and can direct inquiries to Telisha Wilson at telisha.wilson@fda.hhs.gov.
    NOTICE OF INTENT TO SOLE SOURCE
    Dept Of Defense
    The Defense Health Agency (DHA) intends to award a sole source contract to The Institute for Functional Medicine for training sessions focused on treating pain without drugs and surgery, specifically through the Applying Functional Medicine in Clinical Practice course. This training aims to enhance the capabilities of healthcare providers in utilizing functional medicine principles, including diagnostics, therapeutics, and lifestyle interventions to improve patient outcomes. The contract will be executed in Bethesda, Maryland, with a deadline for interested parties to express their capabilities by 10:00 AM EST on January 22, 2025, via email to Judith S. Meynard at judith.s.meynard.ctr@health.mil, with a copy to Erica S. Oh at erica.s.oh.civ@health.mil.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Notice of Intent to Sole Source – Cardinal Health, Inc.
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) intends to award a fixed-price purchase order to Cardinal Health, Inc. for the procurement of Floxuridine Vials, specifically for patient care at the NIH Clinical Center in Bethesda, Maryland. The requirement includes 10 units of Floxuridine for Injection, catalog number 0143-9270-01, which is exclusively distributed by Cardinal Health, Inc. in the United States, highlighting the critical nature of this medication for patient treatment. Interested parties may express their interest and capabilities to Kristin Nagashima at kristin.nagashima@nih.gov by February 10, 2025, at 4 PM EST, as this acquisition is being conducted under the Simplified Acquisition Procedures of the Federal Acquisition Regulation.
    Notice of Intent to Sole Source – TheraDoc subscription
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) Clinical Center intends to award a firm fixed-price purchase order for subscription services related to the TheraDoc application, exclusively owned by Premier Healthcare LLC. This procurement aims to secure applications, support, maintenance, and training for the TheraDoc clinical surveillance solution, which is critical for enhancing healthcare delivery and patient safety. The acquisition will follow the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, allowing for a sole-source solicitation due to the unique nature of the services required. Interested parties may express their capabilities and submit comments to the NIH by November 21, 2024, with inquiries directed to Ryssa Nix at Ryssa.nix@nih.gov.
    Milliflex Rapid 2.0
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking responses for a Sources Sought Notice regarding the acquisition of the Milliflex Rapid 2.0 microbial detection system. This procurement aims to enhance quality control testing for bioburden contamination in pharmaceutical products, necessitating a system that is compatible with the existing Milliflex Oasis filtration pump currently in use. The initiative is critical for ensuring compliance with quality control standards in pharmaceutical manufacturing, thereby bolstering the FDA's capabilities in evaluating rapid microbial detection methods. Interested vendors must submit their responses by January 30, 2024, at 12:00 PM ET, directed to Contract Specialist Iris Johnson at Iris.Johnson1@fda.hhs.gov and Contracting Officer Maria Finan at Linda.Finan@fda.hhs.gov.
    6505--INTENT TO SOLE SOURCE- GALIFOLD 123MG
    Veterans Affairs, Department Of
    The Department of Veterans Affairs intends to procure Galafold (migalastat) 123mg through a sole source solicitation, specifically identified as 36C24725Q0299. This procurement is crucial for the Veterans Affairs healthcare system, as Galafold is a specialized pharmaceutical product necessary for treating specific medical conditions affecting veterans. The contracting office, located in Augusta, Georgia, has set a response deadline for January 21, 2025, at 12:00 PM Eastern Time, and interested parties should direct their inquiries to Holly Bowing via email, as Recovery Act funds are not applicable for this procurement. The notice will be archived 60 days after the response deadline.
    PRIMO Software Licensing
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide PRIMO Software Licensing and Maintenance Support Services. The procurement involves supplying 21 PRIMO software licenses for a base year, with two additional option years, to ensure the continuous operation of the FDA's CFSAN CAEMS system. This software is crucial for pharmacovigilance and regulatory compliance, enhancing the FDA's capabilities in monitoring food safety. Interested parties must submit their quotes by August 26, 2024, and are encouraged to contact Roosevelt Walker at roosevelt.walker@fda.hhs.gov for further details. The contract will be awarded as a firm-fixed-price purchase order, emphasizing compliance with federal acquisition regulations and accessibility standards.
    Hardy Diagnostic Reagents and Supplies
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract to Hardy Diagnostics for the procurement of culture media and organism supplies necessary for cGMP Sterility Testing Services. The primary objective is to ensure compliance with FDA regulations by utilizing cGMP quality materials that have been rigorously validated, as these supplies are critical for the isolation and identification of pathogens affecting critically ill patients. The contract will cover a base period of twelve months with an option for an additional three months, and interested vendors capable of providing similar products are encouraged to submit capability statements by the specified deadline. For further inquiries, potential respondents may contact Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov.